219 related articles for article (PubMed ID: 22261805)
1. CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma.
Aoe K; Amatya VJ; Fujimoto N; Ohnuma K; Hosono O; Hiraki A; Fujii M; Yamada T; Dang NH; Takeshima Y; Inai K; Kishimoto T; Morimoto C
Clin Cancer Res; 2012 Mar; 18(5):1447-56. PubMed ID: 22261805
[TBL] [Abstract][Full Text] [Related]
2. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
Wang YY; Zhang H; Bai H; Wang SH; Wu MN; An TT; Zhao J; Zhuo ML; Duan JC; Wang ZJ; Wang J
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):162-8. PubMed ID: 23856136
[TBL] [Abstract][Full Text] [Related]
3. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
Zucali PA; Simonelli M; Michetti G; Tiseo M; Ceresoli GL; Collovà E; Follador A; Lo Dico M; Moretti A; De Vincenzo F; Lorenzi E; Perrino M; Giordano L; Farina G; Santoro A; Garassino M
Lung Cancer; 2012 Mar; 75(3):360-7. PubMed ID: 21937142
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines.
Amatya VJ; Takeshima Y; Kushitani K; Yamada T; Morimoto C; Inai K
Oncol Rep; 2011 Dec; 26(6):1369-75. PubMed ID: 21894438
[TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
Zucali PA; Giovannetti E; Destro A; Mencoboni M; Ceresoli GL; Gianoncelli L; Lorenzi E; De Vincenzo F; Simonelli M; Perrino M; Bruzzone A; Thunnissen E; Tunesi G; Giordano L; Roncalli M; Peters GJ; Santoro A
Clin Cancer Res; 2011 Apr; 17(8):2581-90. PubMed ID: 21262916
[TBL] [Abstract][Full Text] [Related]
6. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
Katirtzoglou N; Gkiozos I; Makrilia N; Tsaroucha E; Rapti A; Stratakos G; Fountzilas G; Syrigos KN
Clin Lung Cancer; 2010 Jan; 11(1):30-5. PubMed ID: 20085865
[TBL] [Abstract][Full Text] [Related]
8. A retrospective study of chemotherapy with and without pemetrexed in malignant pleural mesothelioma.
Higashiguchi M; Suzuki H; Hirashima T; Kobayashi M; Goya S; Okamoto N; Matsuura Y; Tamiya M; Morishita N; Tsumori T; Kawase I
Anticancer Res; 2012 Feb; 32(2):609-13. PubMed ID: 22287752
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed in malignant pleural mesothelioma and the clinical outcome.
Knuuttila A; Salomaa ER; Saikkonen S; Hurme S; Salo J
Clin Respir J; 2012 Apr; 6(2):96-103. PubMed ID: 21651743
[TBL] [Abstract][Full Text] [Related]
10. Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma.
Yamamoto J; Ohnuma K; Hatano R; Okamoto T; Komiya E; Yamazaki H; Iwata S; Dang NH; Aoe K; Kishimoto T; Yamada T; Morimoto C
Br J Cancer; 2014 Apr; 110(9):2232-45. PubMed ID: 24743707
[TBL] [Abstract][Full Text] [Related]
11. Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma.
Gordon GJ; Mani M; Mukhopadhyay L; Dong L; Edenfield HR; Glickman JN; Yeap BY; Sugarbaker DJ; Bueno R
J Pathol; 2007 Mar; 211(4):447-54. PubMed ID: 17253596
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study.
Kuribayashi K; Voss S; Nishiuma S; Arakawa K; Nogi Y; Mikami K; Kudoh S
Lung Cancer; 2012 Mar; 75(3):353-9. PubMed ID: 21890228
[TBL] [Abstract][Full Text] [Related]
13. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
[TBL] [Abstract][Full Text] [Related]
14. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
Schaefer NG; Veit-Haibach P; Soyka JD; Steinert HC; Stahel RA
Eur J Radiol; 2012 Jan; 81(1):e19-25. PubMed ID: 21129871
[TBL] [Abstract][Full Text] [Related]
15. Is pleurectomy and decortication superior to palliative care in the treatment of malignant pleural mesothelioma?
Zahid I; Sharif S; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 May; 12(5):812-7. PubMed ID: 21345818
[TBL] [Abstract][Full Text] [Related]
16. Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma.
Gordon GJ; Mani M; Mukhopadhyay L; Dong L; Yeap BY; Sugarbaker DJ; Bueno R
J Pathol; 2007 Mar; 211(4):439-46. PubMed ID: 17253597
[TBL] [Abstract][Full Text] [Related]
17. Life after first-line chemotherapy in malignant pleural mesothelioma: a North-East England experience.
Steer J; Bough G; Razak AR; Meachery GJ; Hughes A
Clin Oncol (R Coll Radiol); 2010 Apr; 22(3):231-5. PubMed ID: 20346340
[TBL] [Abstract][Full Text] [Related]
18. A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma.
Zimling ZG; Sørensen JB; Gerds TA; Bech C; Andersen CB; Santoni-Rugiu E
Cancer Chemother Pharmacol; 2012 Nov; 70(5):743-54. PubMed ID: 22960937
[TBL] [Abstract][Full Text] [Related]
19. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
Righi L; Papotti MG; Ceppi P; Billè A; Bacillo E; Molinaro L; Ruffini E; Scagliotti GV; Selvaggi G
J Clin Oncol; 2010 Mar; 28(9):1534-9. PubMed ID: 20177021
[TBL] [Abstract][Full Text] [Related]
20. [First-line treatment with pemetrexed in association with cisplatin in patients with non-operable malignant pleural mesothelioma].
Burgin M; Gairard-Dory A-; Mennecier B; Molard A; Beretz L; Quoix A-
Rev Pneumol Clin; 2009 Apr; 65(2):75-83. PubMed ID: 19375046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
